Prakiraan pendapatan perusahaan: Cardiff Oncology Inc. (CRDF)

Cardiff Oncology (CRDF) - logo korporat

Cardiff Oncology, Inc. (CRDF) is developing a precision cancer treatment system via the Onvansertib inhibitor, which benefits from unique patent protection. The absence of current sales makes financial stability dependent on investments and regulatory verdicts. A critical bet on a single drug for colorectal cancer therapy creates a significant single-product risk. The company's future sales projections reflect a market consensus, where the 0.00 mark captures this indicator.

Volume dodolan sing dikarepake perusahaan: Cardiff Oncology, Inc. (CRDF) kanggo 04.07.2022 - 17.11.2026

Ringkesan rincian data analitis Cardiff Oncology (CRDF)

- nilai saham lan prakiraan konsensus rega:
- indikator kapitalisasi bursa perusahaan:
Pambiji fundamental:Cardiff Oncology CRDF
Sampel barang cardiffoncology.com

This indicator quantifies the impact of corporate events on projected revenue, converting the news flow regarding mergers and restructurings into a dynamic assessment of future cash flows. By analyzing the expected trading volumes of the company, an investor can track how progress in developing targeted protein inhibitors for prostate and colorectal cancer therapies adjusts the commercialization potential of Cardiff Oncology, Inc. (CRDF) drugs.

Pesaing wigati

Prakiraan pendapatan perusahaan Incyte Pharma (INCY)|Prakiraan pendapatan perusahaan HCM (Hutchison MediPharma)|Prakiraan pendapatan perusahaan Nuvation Pharma NUVB|Day One Biopharmaceuticals Inc - Prakiraan pendapatan perusahaan|MNPR - Prakiraan pendapatan perusahaan|Volume dodolan sing dikarepake perusahaan Inhibrx Biosciences|IMAB: Prakiraan volume dodolan|Prakiraan dodolan perusahaan Fennec Pharmaceuticals Inc FENC|Volume dodolan mangsa ngarep perusahaan HRTX|Volume dodolan sing dikarepake perusahaan Nuvectis Pharma, Inc. NVCT|Volume dodolan mangsa ngarep perusahaan CHRS (Coherus BioSciences, Inc)|CRBP (Corbus Pharmaceuticals Holdings) - Pendapatan mangsa ngarep perusahaan|BeyondSpring Inc. - Volume dodolan mangsa ngarep perusahaan|Prakiraan volume pendapatan perusahaan BCAB (BioAtla Corp)|Lixte Biotechnology Holdings - Prakiraan volume dodolan|Pendapatan mangsa ngarep perusahaan CTXR (citiuspharma.com)|CLRB: Prakiraan volume dodolan|Volume dodolan sing dikarepake perusahaan biolinerx.com (BLRX)|Prakiraan pendapatan perusahaan Can-Fite BioPharma Ltd.|APRE: Pendapatan mangsa ngarep perusahaan|Prakiraan volume dodolan KZIA|Prakiraan volume dodolan Silexion Therapeutics Corp. (SLXN)|Prakiraan pendapatan perusahaan NuCana PLC NCNA|CMRX (Chimerix) - Pendapatan sing dikarepake perusahaan|CYCC: Volume dodolan mangsa ngarep perusahaan|Volume dodolan sing dikarepake perusahaan g1therapeutics.com|Kronos Bio Inc (KRON) - Prakiraan pendapatan perusahaan|Kintara (KTRA) - Prakiraan volume dodolan|Prakiraan pendapatan perusahaan Oncternal Therapeutics, Inc.|Volume dodolan sing dikarepake perusahaan portagebiotech.com PRTG